WallStSmart

Novartis AG ADR (NVS)vsTalkspace Inc (TALK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 23636% more annual revenue ($56.58B vs $238.37M). NVS leads profitability with a 23.9% profit margin vs 0.5%. NVS earns a higher WallStSmart Score of 49/100 (D+).

NVS

Hold

49

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

TALK

Hold

41

out of 100

Grade: D

Growth: 9.3Profit: 4.0Value: 5.0Quality: 7.8
Piotroski: 4/9Altman Z: 3.95
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-69.7%)

Margin of Safety

-69.7%

Fair Value

$91.58

Current Price

$155.41

$63.83 premium

UndervaluedFair: $91.58Overvalued

Intrinsic value data unavailable for TALK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$296.54B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

TALK3 strengths · Avg: 9.3/10
EPS GrowthGrowth
181.1%10/10

Earnings expanding 181.1% YoY

Altman Z-ScoreHealth
3.9510/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
18.2%8/10

18.2% revenue growth

Areas to Watch

NVS4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
4.192/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

TALK4 concerns · Avg: 3.0/10
Market CapQuality
$869.41M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.0%3/10

ROE of 1.0% — below average capital efficiency

Profit MarginProfitability
0.5%3/10

0.5% margin — thin

Operating MarginProfitability
0.3%3/10

Operating margin of 0.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : TALK

The strongest argument for TALK centers on EPS Growth, Altman Z-Score, Revenue Growth. Revenue growth of 18.2% demonstrates continued momentum.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Bear Case : TALK

The primary concerns for TALK are Market Cap, Return on Equity, Profit Margin. Thin 0.5% margins leave little buffer for downturns.

Key Dynamics to Monitor

NVS profiles as a declining stock while TALK is a growth play — different risk/reward profiles.

TALK carries more volatility with a beta of 1.07 — expect wider price swings.

TALK is growing revenue faster at 18.2% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (49/100 vs 41/100), backed by strong 23.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Talkspace Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Talkspace Inc. is a virtual behavioral healthcare company. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?